This week, the EMA released a reflection paper on using artificial intelligence and machine learning throughout a medicine’s product life cycle. The paper recommends a risk-based approach that weighs patient safety and integrity of development data. The paper is scheduled for consultation through the end of the year.
In April 2021, the E.U. released both a coordinated plan on artificial intelligence (AI) and a proposal for a regulation.
Fill out the form to read the full article.